Immunotherapy of high-grade gliomas: Preclinical in vivo experiments in animal models

Neuromethods

Volumn 77, Issue , 2013, Pages 245-273

  Batich, Kristen A ^a   Choi, Bryan D ^a,b   Mitchell, Duane A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; DC vaccines; Dendritic cells; Gliomas; Immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE; RNA; TOTAL TUMOR RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL MEDIATED CYTOTOXICITY; DISEASE MODEL; DRUG TOXICITY; ELECTROPORATION; GLIOBLASTOMA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA EXTRACTION;

ANIMALIA; MURINAE;

EID: 84870545924     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/7657_2012_38     Document Type: Article

References (164)

1. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-2966
2. Gilboa E, Nair SK, Lyerly HK (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46:82-877
3. Nair SK, Boczkowski D, Snyder D, Gilboa E (1997) Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589-5977
4. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-3222
5. Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222:70-1000
6. Imperato JP, Paleologos NA, Vick NA (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28:818-8222
7. Mitchell DA, Fecci PE, Sampson JH (2003) Adoptive immunotherapy for malignant glioma. Cancer J 9:157-1666
8. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-13822
9. Sehgal A, Berger MS (2000) Basic concepts of immunology and neuroimmunology. Neurosurg Focus 9:1-66
10. Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61:738-7433
11. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD (1986) Immunobiology of human gliomas. Semin Oncol 13:94-1099
12. Owens T, Renno T, Taupin V, Krakowski M (1994) Inflammatory cytokines in the brain: Does the CNS shape immune responses? Immunol Today 15:566-5711
13. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G et al (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16-255
14. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS et al (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50:158-164, discussion 164-1566
15. Mitchell DA, Sampson JH (2009) Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 6:527-5388
16. Medawar PB (1948) Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58-699
17. Barker CF, Billingham RE (1977) Immunologically privileged sites [Review]. Adv Immunol 25:1-544
18. Billingham RE, Boswell T (1953) Studies on the problem of corneal homografts. Proc R Soc Lond B Biol Sci 141:392-4066
19. Becher B, Bechmann I, Greter M (2006) Antigen presentation in autoimmunity and CNS inflammation: How T lymphocytes recognize the brain. J Mol Med 84:532-5433
20. Hickey WF (2001) Basic principles of immunological surveillance of the normal central nervous system. Glia 36:118-1244
21. Bechmann I (2005) Failed central nervous system regeneration: A downside of immune privilege? Neuromolecular Med 7:217-2288
22. Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol Today 13:507-5122
23. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I (2006) Tcells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80:797-8011
24. Carson MJ, Sutcliffe JG, Campbell IL (1999) Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J Neurosci Res 55:127-1344
25. Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF et al (2006) How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107:806-8122
26. Karman J, Ling C, Sandor M, Fabry Z (2004) Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 173:2353-23611
27. Lees JR, Archambault AS, Russell JH (2006) T-cell trafficking competence is required for CNS invasion. J Neuroimmunol 177:1-100
28. Ploix CC, Noor S, Crane J, Masek K, Carter W, Lo DD et al (2011) CNS-derived CCL211 is both sufficient to drive homeostatic CD4+ T cell proliferation and necessary for efficient CD4+ T cell migration into the CNS parenchyma following Toxoplasma gondii infection. Brain Behav Immun 25:883-8966
29. Fine HA (1995) Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 13:827-8466
30. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294-33022
31. McVicarDW, Davis DF, Merchant RE (1992) In vitro analysis of the proliferative potential of T cells from patients with brain tumor: Glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 76:251-2600
32. Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT et al (2007) IL-21 counteracts the regulatory T cellmediated suppression of human CD4+ T lymphocytes. J Immunol 178:732-7399
33. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA (2001) A role for TGF-beta in the generation and expansion of CD4 + CD25+ regulatory T cells from human peripheral blood. J Immunol 166:7282-72899
34. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10:133-1466
35. Skog J (2006) Glioma-specific antigens for immune tumor therapy. Expert Rev Vaccines 5:793-8022
36. Perry VH (1998) A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol 90:113-1211
37. Schmidtmayer J, Jacobsen C, Miksch G, Sievers J (1994) Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: Membrane currents. Glia 12:259-2677
38. Streit WJ, Graeber MB (1993) Heterogeneity of microglial and perivascular cell populations: Insights gained from the facial nucleus paradigm. Glia 7:68-744
39. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG (1993) Microglia in degenerative neurological disease. Glia 7:84-922
40. Becher B, Antel JP (1996) Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 18:1-100
41. Sedgwick JD, Ford AL, Foulcher E, Airriess R (1998) Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts. J Immunol 160:5320-53300
42. Ulvestad E, Williams K, Bo L, Trapp B, Antel J, Mork S (1994) HLA class II molecules (HLA-DR,-DP,-DQ) on cells in the human CNS studied in situ and in vitro. Immunology 82:535-5411
43. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335-3399
44. Becher B, Prat A, Antel JP (2000) Brain-immune connection: Immuno-regulatory properties of CNS-resident cells. Glia 29:293-3044
45. Aloisi F (2001) Immune function of microglia. Glia 36:165-1799
46. Li H, Newcombe J, Groome NP, Cuzner ML (1993) Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropathol Appl Neurobiol 19:214-2233
47. SlobodovU,Reichert F,MirskiR,Rotshenker S (2001) Distinct inflammatory stimuli induce different patterns of myelin phagocytosis and degradation in recruited macrophages. Exp Neurol 167:401-4099
48. Williams K, Ulvestad E, Waage A, Antel JP, McLaurin J (1994) Activation of adult human derived microglia by myelin phagocytosis in vitro. J Neurosci Res 38:433-4433
49. Olson JK, Eagar TN, Miller SD (2002) Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J Immunol 169:2719-27266
50. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F (2000) Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 157:1991-20022
51. Irani DN (1998) The susceptibility of mice to immune-mediated neurologic disease correlates with the degree to which their lymphocytes resist the effects of brain-derived gangliosides. J Immunol 161:2746-27522
52. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR (2007) Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 179:845-8533
53. Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR4 expression mediates glioma cell invasiveness. Oncogene 25:2801-28066
54. Ehtesham M, Yuan X, Kabos P, Chung NH, Liu G, Akasaki Y, Black KL, Yu JS (2004) Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 6:287-2933
55. Mitchell DA, Karikari I, Cui X, Xie W, Schmittling R, Sampson JH (2008) Selective modification of antigen-specific T cells by RNA electroporation. HumGene Ther 19:511-5211
56. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1-277
57. Foley EJ (1952) Immunity of C3H mice to lymphosarcoma 6-C3H-Ed following regression of the implanted tumor. Proc Soc Exp BiolMed 80:675-6777
58. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835-8377
59. Sjogren HO (1961) Further studies on the induced resistance against isotransplantation of polyoma tumors. Virology 15:214-2199
60. Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. Science 183:534-5366
61. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-8777
62. Kirchgessner CU, Patil CK, Evans JW, Cuomo CA, Fried LM, Carter T, Oettinger MA, Brown JM (1995) DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 267:1178-11833
63. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al (2001) IFNg and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 410:1107-11111
64. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-1488
65. Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129-1388
66. O'Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10:801-8055
67. Bierie B, Moses HL (2006) Tumor microenvironment: TGFb: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-5200
68. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG (2005) Gene therapy and targeted toxins for glioma. Curr Gene Ther 5:535-5577
69. Candolfi M, Curtin JF, Nichols WS, Muhammad AKMG, King GD, Pluhar GE et al (2007) Intracranial glioblastoma models in preclinical neurooncology: Neuropathological characterization and tumor progression. J Neurooncol 85:133-1488
70. Kim C, Hong M, Park S, Kim C, Park M, Sohn H et al (2006) Enhancement of antitumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 55:1309-13199
71. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP et al (1997) Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365-13733
72. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF (1994) A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9 L gliosarcoma. J Neurooncol 22:191-2000
73. Tzeng JJ, Barth RF, Orosz CG, James SM (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51:2373-23788
74. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: The 9 L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-1022
75. Muhammad AKMG, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y et al (2009) Anti-glioma immunological memory in response to conditional cytotoxic/immunestimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15:6113-61277
76. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barciaet C et al (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 10:1071-10844
77. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C (2005) Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65:7194-72044
78. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK et al (2009) Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity. Clin Cancer Res 15: 4401-44144
79. Weiss W, Israel M, Cobbs C, Holland E, James D, Louis D et al (2002) Neuropathology of genetically engineered mice: Consensus report and recommendations from an international forum. Oncogene 21:7453-74633
80. Ding H, Nagy A, Gutmann D, Guha A (2000) Astrocytoma models. Neurosurg Focus 8:1-77
81. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-1766
82. Cho SY, Ravasi L, Szajek LP, Seidel J, Green MV, Fine HA et al (2005) Evaluation of (76) Br-FBAUas a PETreporter probe forHSV1-tk gene expression imaging using mouse models of human glioma. J Nucl Med 46:1923-19300
83. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM (1998) Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58:4654-46599
84. Lund EL, Bastholm L, Kristjansen PE (2000) Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971-9788
85. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I et al (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9:5370-53799
86. Shen S, Khazaeli MB, Gillespie GY, Alvarez VL (2005) Radiation dosimetry of 131Ichlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol 71:113-1199
87. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK (2004) Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 101:1004-10111
88. Cirielli C, Inyaku K, Capogrossi MC, Yuan X, Williams JA (1999) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J Neurooncol 43:99-1088
89. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97:6803-68088
90. Gromeier M, Solecki D, Patel DD,Wimmer E (2000) Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: Implications for the pathogenesis of poliomyelitis. Virology 273:248-2577
91. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS et al (2007) Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67:5957-59644
92. Vatakis DN, Koya RC, Nixon CC,Wei L, Kim SG, Avancena P et al (2011) Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci USA 108:E1408-E14166
93. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50:201-2122
94. Harvald B (1989) Genetic epidemiology of Greenland. Clin Genet 36:364-3677
95. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173:1007-10155
96. McLaughlin PM, Kroesen BJ, Harmsen MC, de Leij L (2001) Cancer immunotherapy: Insights from transgenic animal models. Crit Rev Oncol Hematol 40:53-766
97. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B (1998) Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 78:216-2222
98. Lauritzsen GF, Weiss S, Dembic Z, Bogen B (1994) Naive idiotypespecific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700-57044
99. Allison J, Stephens LA, Kay TW, Kurts C, Heath WR, Miller JF et al (1998) The threshold for autoimmune T cell killing is influenced by B7-1. Eur J Immunol 28:949-9600
100. Bluming AZ, Ziegler JL (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet 2:105-1066
101. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-13344
102. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821-8255
103. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-8566
104. Dobrikova EY, Broadt T, Poiley-Nelson J, Yang X, Soman G, Giardina S et al (2008) Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 16:1865-18722
105. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Penny MA et al (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93:903-9122
106. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-4722
107. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60:1028-10344
108. Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1-77
109. Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719-17222
110. Zhou WZ, Hoon D, Huang SKS, Fujii S, Hashimoto K, Morishita R et al (1999) RNA melanoma vaccine: Induction of antitumor immunity by human glycoprotein 1000 mRNA immunization. Hum Gene Ther 10:2719-27244
111. Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, Cao X (1999) Enhanced therapeutic efficacy of tumorRNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther 10:1151-11611
112. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177-11822
113. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364-3699
114. Mitchell DA, Nair SK (2000) RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-10699
115. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-8544
116. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA et al (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28:258-2677
117. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101(Suppl 2):14639-146455
118. Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J et al (1994) Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 38:299-3033
119. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF et al (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731-17377
120. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28:53-622
121. Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol 26:485-4955
122. Plautz GE, Shu S (2001) Adoptive immunotherapy of CNS malignancies. Cancer Chemother Biol Response Modif 19:327-3388
123. Charalambous C, Pen LB, Su YS, Milan J, Chen TC, Hofman FM (2005) Interleukin-8 differentially regulates migration of tumorassociated and normal human brain endothelial cells. Cancer Res 65:10347-103544
124. Morita M, Kasahara T, Mukaida N, Matsushima K, Nagashima T, Nishizawa M et al (1993) Induction and regulation of IL-8 and MCAF production in human brain tumor cell lines and brain tumor tissues. Eur Cytokine Netw 4:351-3588
125. Nitta T, Allegretta M, Okumura K, Sato K, Steinman L (1992) Neoplastic and reactive human astrocytes express interleukin-8 gene. Neurosurg Rev 15:203-2077
126. van Den Pol AN, Mocarski E, Saederup N, Vieira J, Meier TJ (1999) Cytomegalovirus cell tropism, replication, and gene transfer in brain. J Neurosci 19:10948-109655
127. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA100:3983-39888
128. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-7377
129. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al (2004) Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res 64:7011-70211
130. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178-151833
131. Bao S,Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-78488
132. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-47400
133. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-12599
134. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-47299
135. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-7600
136. Johannessen TC, Wang J, Skaftnesmo KO, Sakariassen PO, Enger PO, Petersen K et al (2009) Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol 35:380-3933
137. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:677
138. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B et al (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66:10247-102522
139. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE et al (1999) A public database for gene expression in human cancers. Cancer Res 59:5403-54077
140. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 102:16013-160188
141. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-31488
142. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-13877
143. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-14666
144. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700-7077
145. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C et al (2005) Coexpression, prognostic significance and predictive value of EGFR. EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27:317-3255
146. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE 2nd, Lally-Goss D et al (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:2773-27799
147. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130-41400
148. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216-2322
149. Hughes MA, Parisi M, Grossman S, Kleinberg L (2005) Primary brain tumors treated with steroids and radiotherapy: Low CD44 counts and risk of infection. Int J Radiat Oncol Biol Phys 62:1423-14266
150. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL (1997) T cell receptormediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-44255
151. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA et al (2006) Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12:4294-43055
152. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S et al (1996) The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-466
153. Brunet JF, Denizot F, LucianiMF, Roux-Dosseto M, Suzan M, Mattei MG et al (1987) A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267-2700
154. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE et al (2007) Systemic CTLA-4 blockade ameliorates gliomainduced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158-21677
155. Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF et al (2006) Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol 174:74-811
156. Sawaya R (1999) Extent of resection in malignant gliomas: A critical summary. J Neurooncol 42:303-3055
157. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430-4466
158. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach B et al (2005) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11:4430-44366
159. Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316-53266
160. Emens LA, Jaffee EM (2003) Toward a breast cancer vaccine: Work in progress. Oncology 17:1200-12111
161. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial Tcell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-55255
162. Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S et al (2003) Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52:632-6377
163. Mitchell DA, Nair SK (2000) RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther 2:176-1811
164. Boon T, De Plaen E, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C et al (1992) Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 13:23-377